Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

Alessia Fraccaroli, MD, Dusan Prevalsek, Sarah Elena Häbe, Veit Bücklein, MD, Christoph Schulz, MD, Heidrun Drolle, Susanne Fritsch, Georg Ledderose, Michael von Bergwelt, MD, Wolfgang Hiddemann, PhD, Johanna Tischer

Blood (2018) 132 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2018-99-119103

Published: 2018

Journal Articles

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Blood (2016) 128 (22): 2224.

https://doi.org/10.1182/blood.V128.22.2224.2224

Published: 2016

Journal Articles

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Dusan Prevalsek, MD, Susanne Fritsch, MD, Max Hubmann, MD, Nicole Engel, MD, Anna-Katharina Zoellner, MD, Thomas Köhnke, MD, Veit Leonhard Bücklein, MD, Christoph Schulz, MD, Friederike Mumm, MD, Christina Theresa Rieger, MD, Georg Ledderose, MD, Hans-Joachim Stemmler, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2015) 126 (23): 4318.

https://doi.org/10.1182/blood.V126.23.4318.4318

Published: 2015

Journal Articles

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Nicole Engel, MD, Wolfgang Hill, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Anna-Katharina Zoellner, MD, Max Hubmann, MD, Veit Buecklein, MD, Andreas Hausmann, MD, Georg Ledderose, MD, Hans-Jochem Kolb, PhD, Wolfgang Hiddemann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 5839.

https://doi.org/10.1182/blood.V124.21.5839.5839

Published: 2014

Journal Articles

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Anna-Katharina Zoellner, Susanne Fritsch, MD, Dusan Prevalsek, MD, Nicole Engel, MD, Roland Reibke, MD, Christina T Rieger, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, Martin Dreyling, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2013) 122 (21): 4544.

https://doi.org/10.1182/blood.V122.21.4544.4544

Published: 2013

Journal Articles

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Johanna Tischer, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Max Hubmann, MD, Veit Bücklein, Anna K Zöllner, MD, Christoph Schulz, MD, Roland Reibke, MD, Nicole Engel, MD, Christina T Rieger, MD, PhD, Christoph Schmid, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, PhD, Andreas Hausmann, MD

Blood (2012) 120 (21): 3071.

https://doi.org/10.1182/blood.V120.21.3071.3071

Published: 2012

Journal Articles

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

Andreas Moosmann, Iris Bigalke, Johanna Tischer, Leah Schirrmann, Julitta Kasten, Stefanie Tippmer, Marina Leeping, Dušan Prevalšek, Gundula Jaeger, Georg Ledderose, Josef Mautner, Wolfgang Hammerschmidt, Dolores J. Schendel, Hans-Jochem Kolb

Blood (2010) 115 (14): 2960–2970.

https://doi.org/10.1182/blood-2009-08-236356

Published: 2010

Journal Articles

Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?.

Hans-Jochem Kolb, Dagmar Bund, PhD, Helga Schmetzer, PhD, Prof, Christoph Schmid, MD, PhD, Raymund Buhmann, MD, Johanna Tischer, MD, Georg Ledderose, MD

Blood (2009) 114 (22): 2258.

https://doi.org/10.1182/blood.V114.22.2258.2258

Published: 2009

Journal Articles

Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation – Follow up

Bernhard Heilmeier, Nadine Stowasser, Gerard Socie, MD, PhD, Maria Teresa van Lint, Andre Tichelli, Nina Salooja, Elke Nekolla, Per T. Ljungman, MD, PhD, Niels Jacobsen, Marie van Weel, Johanna Tischer, Georg Ledderose, Theodor M. Fliedner, Hans-Jochem Kolb

Blood (2008) 112 (11): 453.

https://doi.org/10.1182/blood.V112.11.453.453

Published: 2008

Journal Articles

Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Family Members as Compared to HLA-Identical Sibling Donors

Hans Jochem Kolb, MD, Iris Bigalke, Dominik Termeer, Susanne Fritsch, Wolfgang Hill, Belinda Simoes, Andreas Hausmann, Christine Falk, Raymund Buhmann, Johanna Tischer, Georg Ledderose

Blood (2008) 112 (11): 3009.

https://doi.org/10.1182/blood.V112.11.3009.3009

Published: 2008

Journal Articles

Bone Marrow Reaction in Patients with Chronic GvHD - An Immunohistochemical Analysis of Microvessels and Lymphocytes.

Wolfgang Hill, MD, Ralf Huss, MD, Johanna Ullmann, Georg Ledderose, MD, Johanna Tischer, MD, Andreas Hausmann, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1963.

https://doi.org/10.1182/blood.V110.11.1963.1963

Published: 2007

Journal Articles

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Christoph Schmid, MD, Johanna Tischer, MD, Matthias Stelljes, MD, Michael Schleuning, MD, Rainer Schwerdtfeger, MD, Ute Hegenbart, MD, Joerg Schubert, MD, Wichard Vogel, MD, Berd Gruhn, MD, Christiane Lallinger, Georg Ledderose, MD, Martin Bornhaeuser, MD, Joachim Kienast, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1651.

https://doi.org/10.1182/blood.V110.11.1651.1651

Published: 2007

Journal Articles

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Hans-Jochem Kolb, MD, PhD, Christoph Schmid, MD, Johanna Tischer, MD, Andreas Haussmann, MD, Andreas Rank, MD, Michael Schleuning, MD, Georg Ledderose, MD

Blood (2006) 108 (11): 324.

https://doi.org/10.1182/blood.V108.11.324.324

Published: 2006

Journal Articles

Treatment of Osteopenia/Osteoporosis after Allogeneic Hematological Cell Transplantation with Zoledronic Acid.

Wolfgang Hill, MD, Johanna Ullmann, Andrea Baur, MD, Georg Ledderose, MD, Johanna Tischer, MD, Dieter Muehlbayer, MD, Andreas Hausmann, MD, Michael Schmidt, Ulrike Haus, Hans-Jochem Kolb, MD

Blood (2006) 108 (11): 3368.

https://doi.org/10.1182/blood.V108.11.3368.3368

Published: 2006

Journal Articles

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

Christoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, Bernd Hertenstein, Eva Mischak-Weissinger, Donald Bunjes, Stephanie v. Harsdorf, Christoph Scheid, Udo Holtick, Hildegard Greinix, Felix Keil, Barbara Schneider, Michael Sandherr, Gesine Bug, Johanna Tischer, Georg Ledderose, Michael Hallek, Wolfgang Hiddemann, Hans-Jochem Kolb

Blood (2006) 108 (3): 1092–1099.

https://doi.org/10.1182/blood-2005-10-4165

Published: 2006

Journal Articles

Risk Factors of HLA-Haploidentical Transplantation Using the Combination of Unmodified Marrow and CD6-Depleted G-CSF Mobilized Blood Cells.

Hans-Jochem Kolb, MD, PhD, Iris Bigalke, MD, Johanna Tischer, MD, Wolfgang Hill, MD, Christine Falk, PhD, Belinda Simoes, MD, Christoph Schmid, MD, Georg Ledderose, MD

Blood (2005) 106 (11): 2907.

https://doi.org/10.1182/blood.V106.11.2907.2907

Published: 2005

Journal Articles

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Barbara Wassmann, Heike Pfeifer, Michael Stadler, Martin Bornhaüser, Gesine Bug, Urban J. Scheuring, Patrick Brück, Matthias Stelljes, Rainer Schwerdtfeger, Nadezda Basara, Jolanta Perz, Donald Bunjes, Georg Ledderose, Rolf Mahlberg, Anja Binckebanck, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2005) 106 (2): 458–463.

https://doi.org/10.1182/blood-2004-05-1746

Published: 2005

Includes: Supplemental data

Journal Articles

Durable Remission after Prophylactic Donor Lymphocyte Transfusion Following Allogeneic Stem Cell Transplantation with Reduced Conditioning for High-Risk AML and MDS.

Michael Schleuning, Christoph Schmid, Georg Ledderose, Johanna Tischer, Meike Humann, Johanna Ullmann, Rainer Schwerdtfeger, PD., Hans-Jochem Kolb

Blood (2004) 104 (11): 299.

https://doi.org/10.1182/blood.V104.11.299.299

Published: 2004

Journal Articles

A Comparison of Acute GVHD after HLA-Haploidentical and HLA-Identical Stem Cell Transplantation.

Wolfgang Hill, MD, Johanna Tischer, MD, Iris Bigalke, MD, Christina Rieger, MD, Georg Ledderose, MD, Hans-Jochem Kolb, MD

Blood (2004) 104 (11): 2151.

https://doi.org/10.1182/blood.V104.11.2151.2151

Published: 2004

Journal Articles

CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation.

Hans-Jochem Kolb, MD, Iris Bigalke, MD, Belinda Simoes, MD, Christine Falk, PhD, Johanna Tischer, MD, Wolfgang Hill, MD, Georg Ledderose, MD

Blood (2004) 104 (11): 978.

https://doi.org/10.1182/blood.V104.11.978.978

Published: 2004

NARROW

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?.

Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation – Follow up

Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Family Members as Compared to HLA-Identical Sibling Donors

Bone Marrow Reaction in Patients with Chronic GvHD - An Immunohistochemical Analysis of Microvessels and Lymphocytes.

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Treatment of Osteopenia/Osteoporosis after Allogeneic Hematological Cell Transplantation with Zoledronic Acid.

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

Risk Factors of HLA-Haploidentical Transplantation Using the Combination of Unmodified Marrow and CD6-Depleted G-CSF Mobilized Blood Cells.

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Durable Remission after Prophylactic Donor Lymphocyte Transfusion Following Allogeneic Stem Cell Transplantation with Reduced Conditioning for High-Risk AML and MDS.

A Comparison of Acute GVHD after HLA-Haploidentical and HLA-Identical Stem Cell Transplantation.

CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only